Unum Therapeutics reported collaboration revenues of $15.3 million for Q4 2019, a significant increase compared to $3.8 million for the same period in 2018, primarily due to the recognition of a portion of the upfront payment from Seattle Genetics, Inc. Net income attributable to common stockholders was $2.3 million, or $0.07 per share, for the fourth quarter of 2019, compared to a net loss of $8.6 million, or ($0.29) per share for the same period of 2018. As of December 31, 2019, Unum had cash and cash equivalents of $37.4 million.